Latest News and Press Releases

EXTON, PA, Oct. 28, 2025 (GLOBE NEWSWIRE) -- The membranous nephropathy (MN) treatment paradigm is on the brink of transformation, with physicians signaling strong interest in novel mechanisms of...

Collaboration leverages OMass’ OdyssionTM platform for the continued development of oral small molecules against a first-in-class target in inflammatory bowel diseaseOMass to receive $20 million...

Collaboration leverages OMass’ OdyssionTM platform for the continued development of oral small molecules against a first-in-class target in inflammatory bowel diseaseOMass to receive $20 million...

Exton, Pennsylvania, Aug. 28, 2025 (GLOBE NEWSWIRE) -- In a newly published edition of Special Topix™: Ophthalmology Pipeline Opportunities 2025 (US), research from Spherix Global Insights with U.S....

LIXTE (NASDAQ: LIXT) publishes new data showing that its lead compound LB-100 can mediate activation of oncogenic signaling, which is toxic to cancer cells

LIXTE Biotechnology (Nasdaq: LIXT) advancing its clinical strategy by focusing on high-need, high-value cancer indications that currently offer limited tre

LIXTE’s (Nasdaq: LIXT) lead compound, LB 100, was featured in Nature Reviews Cancer editorial titled “Too Much of a Good Thing”

Austin, TX, USA, June 23, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Alzheimer’s Drug Market Size, Trends and Insights By Type of Drug...

Washington D.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Roche to the Bio-Hermes-002 study. This collaboration will enhance this...

TORONTO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University Health Network Research Ethics...